Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14472702 | 0.92 | DNM1 (0.42) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL25634934 | 0.90 | DNM1 (0.46) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL8854163 | 0.90 | DNM1 (0.46) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL2524017 | 0.88 | TSHR (0.35) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL7776810 | 0.83 | DNM1 (0.32) | CA12CA1CA9DNM1TSHR | |
| SCHEMBL12243063 | 0.83 | DNM1 (0.43) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL5071934 | 0.82 | — | — | |
| SCHEMBL24965367 | 0.82 | — | — | |
| SCHEMBL26502986 | 0.81 | DNM1 (0.48) | CA12CA1CA9CA2DNM1 | |
| SCHEMBL26502982 | 0.81 | DNM1 (0.48) | CA12CA1CA9CA2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0623578-B1 | Process for the preparation of dichloroacetylchloride | HOECHST AG (DE) | 1997-08-13 | — | — | EP | claimed |
| US-5433831-A | Process for the preparation of dichloroacetyl chloride | HOECHST AKTIENGESELLCHAFT (DE) | 1995-07-18 | — | — | US | claimed |
| EP-0623578-A1 | Process for the preparation of dichloroacetylchloride | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-09 | — | — | EP | claimed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230285332-A1 | TOPICAL ANESTHETICS | PTC INNOVATIONS LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11639329-B2 | Lipids for use in lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2023-05-02 | — | — | US | disclosed |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
| US-20220389021-A1 | INHIBITORS OF KRAS G12C | BEONE MEDICINES I GMBH (CH) | 2022-12-08 | — | — | US | disclosed |
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| EP-0838508-B1 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORP (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0623578-B1 | Process for the preparation of dichloroacetylchloride | HOECHST AG (DE) | 1997-08-13 | — | — | EP | disclosed |
| US-5433831-A | Process for the preparation of dichloroacetyl chloride | HOECHST AKTIENGESELLCHAFT (DE) | 1995-07-18 | — | — | US | disclosed |
| EP-0623578-A1 | Process for the preparation of dichloroacetylchloride | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | EDNRA, EDNRB, ESRRB | CA12 4530/4885CA1 4632/4885CA9 3984/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | CA12 3727/4885CA1 4251/4885CA9 4374/4885 |
| US-11639329-B2 | Lipids for use in lipid nanoparticle formulations | PHOSPHO1, NPC1, NPC1L1 | CA12 1761/4885CA1 2028/4885CA9 2749/4885 |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | BTK, BLK, SYK | CA12 4841/4885CA1 4328/4885CA9 3717/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | CA12 3727/4885CA1 4251/4885CA9 4374/4885 |
| US-20220389021-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CA12 4146/4885CA1 3801/4885CA9 2266/4885 |
| US-20230285332-A1 | TOPICAL ANESTHETICS | OR10J3, ALKBH3, CHRM3 | CA12 2399/4885CA1 2573/4885CA9 1410/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | CA12 3727/4885CA1 4251/4885CA9 4374/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | CA12 4043/4885CA1 4560/4885CA9 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.